Y-mAbs Therapeutics - YMAB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $29.50
  • Forecasted Upside: 101.64 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$14.63
▲ +0.23 (1.60%)

This chart shows the closing price for YMAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Y-mAbs Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for YMAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for YMAB

Analyst Price Target is $29.50
▲ +101.64% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Y-mAbs Therapeutics in the last 3 months. The average price target is $29.50, with a high forecast of $63.00 and a low forecast of $17.00. The average price target represents a 101.64% upside from the last price of $14.63.

This chart shows the closing price for YMAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Y-mAbs Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/9/2022Morgan StanleyBoost TargetEqual Weight$15.00 ➝ $17.00Low
6/23/2022BMO Capital MarketsInitiated CoverageOutperform$27.00Low
5/10/2022WedbushLower TargetOutperform$28.00 ➝ $21.00High
4/29/2022HC WainwrightReiterated RatingBuy$63.00High
4/28/2022WedbushLower Target$36.00 ➝ $28.00High
2/28/2022HC WainwrightLower TargetBuy$68.00 ➝ $63.00High
2/3/2022GuggenheimInitiated CoverageBuy$22.00Medium
1/3/2022JPMorgan Chase & Co.Lower TargetNeutral$30.00 ➝ $27.00High
12/22/2021HC WainwrightReiterated RatingBuy$68.00Medium
11/19/2021Morgan StanleyInitiated CoverageEqual Weight$25.00Medium
11/16/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$57.00 ➝ $30.00High
10/8/2021HC WainwrightReiterated RatingBuy$68.00Low
9/14/2021HC WainwrightReiterated RatingBuy$68.00Medium
8/9/2021HC WainwrightReiterated RatingBuy$68.00Medium
7/7/2021HC WainwrightReiterated RatingBuy$68.00High
6/28/2021HC WainwrightLower TargetBuy$70.00 ➝ $68.00Low
5/7/2021Bank of AmericaUpgradeNeutral ➝ BuyHigh
4/21/2021WedbushLower TargetOutperform$67.00 ➝ $52.00High
3/22/2021JPMorgan Chase & Co.Reiterated RatingOverweight$52.00Low
3/1/2021HC WainwrightBoost TargetBuy$65.00 ➝ $70.00Low
1/15/2021Bank of AmericaDowngradeBuy ➝ Neutral$56.00High
12/17/2020WedbushBoost TargetOutperform$52.00 ➝ $71.00High
12/17/2020BarclaysBoost TargetOverweight$55.00 ➝ $65.00High
11/12/2020Morgan StanleyBoost TargetEqual Weight$42.00 ➝ $45.00Medium
11/9/2020BarclaysBoost TargetPositive ➝ Overweight$47.00 ➝ $53.00Medium
11/9/2020HC WainwrightBoost TargetBuy$52.00 ➝ $65.00Medium
7/15/2020Morgan StanleyBoost TargetEqual Weight$39.00 ➝ $42.00High
7/1/2020HC WainwrightReiterated RatingBuy$52.00Low
5/11/2020WedbushBoost TargetOutperform$41.00 ➝ $48.00Medium
5/11/2020HC WainwrightBoost TargetBuy$41.00 ➝ $52.00Medium
5/4/2020BarclaysInitiated CoverageOverweight$44.00Low
5/1/2020Janney Montgomery ScottInitiated CoverageBuyHigh
4/29/2020Morgan StanleyInitiated CoverageEqual WeightHigh
3/12/2020CowenReiterated RatingBuyHigh
1/28/2020HC WainwrightReiterated RatingBuy$40.00 ➝ $41.00Medium
12/24/2019JPMorgan Chase & Co.Initiated CoverageOverweight$39.00 ➝ $39.00Medium
12/12/2019CowenInitiated CoverageBuyLow
12/12/2019HC WainwrightReiterated RatingBuy$40.00Medium
12/2/2019HC WainwrightReiterated RatingBuy$40.00High
11/27/2019GuggenheimInitiated CoverageBuy$40.00Low
11/19/2019GuggenheimInitiated CoverageBuy$40.00High
11/18/2019HC WainwrightReiterated RatingBuy$40.00Low
11/4/2019HC WainwrightReiterated RatingBuyLow
10/29/2019HC WainwrightBoost TargetBuy$43.00Low
10/28/2019CowenReiterated RatingBuyLow
9/3/2019WedbushInitiated CoverageOutperform$38.00Medium
8/26/2019HC WainwrightSet TargetBuy$40.00Low
7/1/2019CowenReiterated RatingBuyLow
6/10/2019HC WainwrightReiterated RatingBuy$36.00 ➝ $40.00High
5/28/2019HC WainwrightSet TargetBuy$36.00High
4/1/2019HC WainwrightInitiated CoverageBuy ➝ Buy$36.00Medium
10/16/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$26.00High
10/16/2018CowenReiterated RatingBuyHigh
10/16/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$35.00High
(Data available from 10/6/2017 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/10/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/9/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/8/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/7/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
9/6/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/6/2022

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Y-mAbs Therapeutics logo
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Read More

Today's Range

Now: $14.63
Low: $13.94
High: $14.84

50 Day Range

MA: $15.98
Low: $13.28
High: $18.96

52 Week Range

Now: $14.63
Low: $6.50
High: $29.24

Volume

3,143 shs

Average Volume

323,934 shs

Market Capitalization

$639.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Y-mAbs Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Y-mAbs Therapeutics in the last twelve months: BMO Capital Markets, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, and Wedbush.
View the latest analyst ratings for YMAB.

What is the current price target for Y-mAbs Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Y-mAbs Therapeutics in the last year. Their average twelve-month price target is $29.50, suggesting a possible upside of 101.6%. HC Wainwright has the highest price target set, predicting YMAB will reach $63.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $17.00 for Y-mAbs Therapeutics in the next year.
View the latest price targets for YMAB.

What is the current consensus analyst rating for Y-mAbs Therapeutics?

Y-mAbs Therapeutics currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe YMAB will outperform the market and that investors should add to their positions of Y-mAbs Therapeutics.
View the latest ratings for YMAB.

What other companies compete with Y-mAbs Therapeutics?

How do I contact Y-mAbs Therapeutics' investor relations team?

Y-mAbs Therapeutics' physical mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company's listed phone number is (646) 885-8505 and its investor relations email address is [email protected] The official website for Y-mAbs Therapeutics is www.ymabs.com. Learn More about contacing Y-mAbs Therapeutics investor relations.